Document Actions

AMC IV

The Lipid Research Group

AMT was founded by researchers from the AMC to develop gene therapies. The Lipid Research Group of prof. Kastelein at the AMC -a leading group in the field of lipoprotein metabolism- exclusively licensed the intellectual property from its LPL related research to AMT for the development of a gene therapy. AMT also exclusively licensed intellectual property on LPL originating from professor Hayden and owned by UBC and used UBC's LPL deficient animal models for its pre-clinical development program in this field. A clinical trial for LPL deficient patients at the AMC is aimed to start end of 2005.

It’s business stupid

What is it with the Dutch that they have such difficulty grabbing business opportunities in a changing world? We have the brains, we have the money and the opportunities are plenty. Still, during the last 40 years hardly any company of substantial size has emerged next to the old industry in the AEX. Oil, food, materials and financial services dominate the landscape.

We have left the environmental challenges to environmentalists, rather then building innovative businesses in solar or wind energy to help face them. We have exported our knowledge on agriculture around the world, and now that we can more intelligently engineer crops we let the opportunity pass due to invalid arguments around GMOs. Now that “kweekersrecht” is being substituted by patent law we complain instead of adapt.

Personal tools

Document Actions

AMC IV

It’s business stupid